Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 21

Sort by

Sort Order Select

Journal Articles

Large B-cell lymphoma after CD19-CAR-T failure: Updated real-world outcomes, prognostic factors, and prediction models

Smith Kungwankiattichai, Sanjog Bastola, Manoj Rai, Amrita Desai, Andy Chen, Craig Okada, Brandon Hayes-Lattin, Stephen Spurgeon, Tanaya Shree, Weerapat Owattanapanich, Staci Williamson, Bashi Ratterree, Rachel Bixler, Chi Phan, Robert Ahrenkiel, Richard Maziarz

Blood (2025) 146 (Supplement 1): 3726.

https://doi.org/10.1182/blood-2025-3726

Published: 2025

Journal Articles

A phase 2 study of prophylactic intrathecal chemotherapy to prevent high-grade immune effector cell–associated neurotoxicity syndrome

Lorena Caulkins, Stephen Spurgeon

Blood (2025) 146 (Supplement 1): 8247.

https://doi.org/10.1182/blood-2025-8247

Published: 2025

Journal Articles

High-dose anakinra to treat refractory immune effector cell-associated neurotoxicity syndrome in CAR T-cell therapy recipients

Blood (2025) 146 (Supplement 1): 928.

https://doi.org/10.1182/blood-2025-928

Published: 2025

Journal Articles

SGR-1505, a potent and selective MALT1 inhibitor with preliminary efficacy in BTKi exposed Waldenström macroglobulinemia (WM) and “double-exposed” CLL/SLL

Blood (2025) 146 (Supplement 1): 3603.

https://doi.org/10.1182/blood-2025-3603

Published: 2025

Journal Articles

Analysis of predictive factors for POD24 in patients with previously untreated mantle cell lymphoma receiving bendamustine-rituximab with or without acalabrutinib in the phase 3 ECHO trial

Chan Cheah, Stephen Spurgeon, Sung-Soo Yoon, Melina Boutin, Eva Gonzalez Barca, Krimo Bouabdallah, Ellie John, Tatjana Krautloher, Victoria Otero, Brad Kahl

Blood (2025) 146 (Supplement 1): 3578.

https://doi.org/10.1182/blood-2025-3578

Published: 2025

Journal Articles

Multicenter real-world outcomes in limited stage (LS) diffuse large B-cell lymphoma (DLBCL) treated with abbreviated immunochemotherapy

Blood (2025) 146 (Supplement 1): 471.

https://doi.org/10.1182/blood-2025-471

Published: 2025

Journal Articles

Postibrutinib outcomes in patients with mantle cell lymphoma

Blood (2016) 127 (12): 1559–1563.

https://doi.org/10.1182/blood-2015-10-673145

Published: 2016

Journal Articles

Final Results of a Phase 1-2 Study of Vorinostat (SAHA), Cladribine, and Rituximab (SCR) Relapsed B-Cell Non-Hodgkin’s Lymphoma and Previously Untreated Mantle Cell Lymphoma

Stephen Spurgeon, MD, Kamal Sharma, DO, David F. Claxton, MD, Christopher Ehmann, MD, Sara Shimko, BS, August Stewart, Samir Parekh, MD, Violetta V. Leshchenko, PhD, Yiyi Chen, PhD, Motomi Mori, Jeffrey J. Pu, MD PhD, Elliot Epner, MD PhD

Blood (2014) 124 (21): 1714.

https://doi.org/10.1182/blood.V124.21.1714.1714

Published: 2014

Journal Articles

Consolidative Autologous Stem Cell Transplant for Double Hit Lymphoma

Andy I Chen, MDPhD, Craig Okada, MD PhD, Nate Gay, MD, Phil Reiss, MD, Stephen Spurgeon, MD, Guang Fan, MD PhD, Rita M. Braziel, MD, Richard T. Maziarz, MD

Blood (2014) 124 (21): 3993.

https://doi.org/10.1182/blood.V124.21.3993.3993

Published: 2014

Journal Articles

Clinical Activity Of Idelalisib (GS-1101), a Selective Inhibitor Of PI3Kδ, In Phase 1 and 2 Trials In Chronic Lymphocytic Leukemia (CLL): Effect Of Del(17p)/TP53 Mutation, Del(11q), IGHV Mutation, and NOTCH1 Mutation

Blood (2013) 122 (21): 1632.

https://doi.org/10.1182/blood.V122.21.1632.1632

Published: 2013

Journal Articles

CX-4945, An Orally Bioavailable Selective Inhibitor of Casein Kinase 2 (CK2), Exhibits Anti-Tumor Activity in Hematologic Malignancies,

Renee C Prins, M.D., Stephen Spurgeon, MD, Jeffrey W Tyner, PhD, Luke B Fletcher, Abdusebur Jemal, Jade A Bryant, BS, Russell T Burke, Bill H Chang, MD, PhD, Tibor Kovacsovics, MD, Brian J. Druker, Marc M Loriaux, MD, PhD

Blood (2011) 118 (21): 3512.

https://doi.org/10.1182/blood.V118.21.3512.3512

Published: 2011

Journal Articles

A Phase I/II Study of Vorinostat (SAHA), Cladribine (2-CdA), and Rituximab Shows Significant Activity in Previously Untreated Mantle Cell Lymphoma

Stephen Spurgeon, MD, Andy I Chen, MD, PhD, Craig Okada, MD, PhD, Samir Parekh, MD, Violetta V. Leshchenko, PhD, Gundula Palmbach, Bashi Ratterree, RN, Nan Subbiah, Christine Capper, RN, Elliot M Epner, MD, PhD

Blood (2011) 118 (21): 441.

https://doi.org/10.1182/blood.V118.21.441.441

Published: 2011

Journal Articles

Phase 1 Study of Tru-016, An Anti-CD37 SMIP™ Protein in Naïve and Relapsed and/or Refractory CLL Patients

Farrukh T Awan, MD, MS, John M. Pagel, MD, PhD, Leslie A Andritsos, MD, Ajay K. Gopal, MD, Richard R. Furman, MD, Stephen Spurgeon, MD, Delva Deauna-Limayo, MD, Scott Stromatt, MD, John C. Byrd, MD

Blood (2011) 118 (21): 1792.

https://doi.org/10.1182/blood.V118.21.1792.1792

Published: 2011

Journal Articles

Phase 1 Study of TRU-016, An Anti-CD37 SMIP™ Protein in Relapsed and/or Refractory NHL Patients

John M. Pagel, MD, PhD, Stephen Spurgeon, MD, Farrukh Awan, MD, MS, Kristie A. Blum, MD, Mark C Lanasa, MD, PhD, Ian W. Flinn, MD, PhD, Scott Stromatt, MD, John C. Byrd, MD, Ajay K. Gopal, MD

Blood (2011) 118 (21): 1636.

https://doi.org/10.1182/blood.V118.21.1636.1636

Published: 2011

Journal Articles

A Highly Selective AKT 1/2 Inhibitor Abrogates AKT Signaling and Is Cytotoxic to Primary Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma Cells

Luke B Fletcher, Stephen Spurgeon, MD, Jeffrey W Tyner, PhD, Brian J Druker, MD, Marc M Loriaux, MD, PhD

Blood (2010) 116 (21): 3594.

https://doi.org/10.1182/blood.V116.21.3594.3594

Published: 2010

Journal Articles

Clinical Safety and Activity In a Phase 1 Study of CAL-101, An Isoform-Selective Inhibitor of Phosphatidylinositol 3-Kinase P110δ, In Patients with Relapsed or Refractory Non-Hodgkin Lymphoma

Brad Kahl, MD, John C. Byrd, MD, Ian W. Flinn, MD, PhD, Nina Wagner-Johnston, MD, Stephen Spurgeon, MD, Don M Benson, Jr, MD, Richard R. Furman, MD, Jennifer R Brown, MD, PhD, Steven Coutre, MD, Brian Lannutti, PhD, Neil A. Giese, Ph.D., Roger G Ulrich, Ph.D., Heather K Webb, Ph.D., Sissy Peterman, Leanne Holes, Albert S Yu, MD

Blood (2010) 116 (21): 1777.

https://doi.org/10.1182/blood.V116.21.1777.1777

Published: 2010

Journal Articles

Cladribine Plus Rituximab Is An Effective Therapy for Newly Diagnosed Mantle Cell Lymphoma

Stephen Spurgeon, MD, Talia Pindyck, MD, Marc M Loriaux, MD, PhD, Craig Okada, MD, PhD, Kamal Abbi, Yiyi Chen, Zunqui Chen, Elana Mater, Elliott Epner, MD, PhD

Blood (2010) 116 (21): 4910.

https://doi.org/10.1182/blood.V116.21.4910.4910

Published: 2010

Journal Articles

Forodesine, a Purine Nucleoside Phosphorylase (PNP) Inhibitor, Shows Clinical Activity In a Phase 2 Trial In Patients with Previously Treated Chronic Lymphocytic Leukemia (CLL) – Interim Analysis

Taimur Sher, MD, Jose Azar, MD, Stephen Spurgeon, MD, John Catalano, MBBS, FRACP, FRCPA, Richard R. Furman, MD, Miles Prince, MD, FRACP, FRCPA, Nancy L. Bartlett, MD, Simon Durrant, MBBS, FRCP, FRCPath, Ralph Boccia, MD, Aisha Masood, MD, Scott Lyman, MS, Jean Cantey-Kiser, William P Sheridan, MB, BS, Asher Chanan-Khan, MD

Blood (2010) 116 (21): 1397.

https://doi.org/10.1182/blood.V116.21.1397.1397

Published: 2010

Journal Articles

Evaluation of CPX-351 (cytarabine:daunorubicin) Liposome Injection Anti-Leukemic Activity Against Primary Patient Leukemia Cells

Jeffrey W Tyner, PhD, Paul Tardi, PhD, Lawrence Mayer, PhD, Luke B Fletcher, Stephen Spurgeon, MD, Tibor Kovacsovics, MD, Marc M Loriaux, MD, PhD

Blood (2010) 116 (21): 2886.

https://doi.org/10.1182/blood.V116.21.2886.2886

Published: 2010

Journal Articles

P505-15, a Highly Selective SYK Inhibitor, Shows Significant Activity In Primary CLL Cells and Is Synergistic with Fludarabine at Low Concentrations

Stephen Spurgeon, MD, Luke B Fletcher, Jeffrey W Tyner, PhD, Brian J Druker, MD, Anjali Pandey, PhD, Uma Sinha, PhD, Marc M Loriaux, MD, PhD

Blood (2010) 116 (21): 2839.

https://doi.org/10.1182/blood.V116.21.2839.2839

Published: 2010

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Large B-cell lymphoma after CD19-CAR-T failure: Updated real-world outcomes, prognostic factors, and prediction models

A phase 2 study of prophylactic intrathecal chemotherapy to prevent high-grade immune effector cell–associated neurotoxicity syndrome

High-dose anakinra to treat refractory immune effector cell-associated neurotoxicity syndrome in CAR T-cell therapy recipients

SGR-1505, a potent and selective MALT1 inhibitor with preliminary efficacy in BTKi exposed Waldenström macroglobulinemia (WM) and “double-exposed” CLL/SLL

Analysis of predictive factors for POD24 in patients with previously untreated mantle cell lymphoma receiving bendamustine-rituximab with or without acalabrutinib in the phase 3 ECHO trial

Multicenter real-world outcomes in limited stage (LS) diffuse large B-cell lymphoma (DLBCL) treated with abbreviated immunochemotherapy

Postibrutinib outcomes in patients with mantle cell lymphoma

Final Results of a Phase 1-2 Study of Vorinostat (SAHA), Cladribine, and Rituximab (SCR) Relapsed B-Cell Non-Hodgkin’s Lymphoma and Previously Untreated Mantle Cell Lymphoma

Consolidative Autologous Stem Cell Transplant for Double Hit Lymphoma

Clinical Activity Of Idelalisib (GS-1101), a Selective Inhibitor Of PI3Kδ, In Phase 1 and 2 Trials In Chronic Lymphocytic Leukemia (CLL): Effect Of Del(17p)/TP53 Mutation, Del(11q), IGHV Mutation, and NOTCH1 Mutation

CX-4945, An Orally Bioavailable Selective Inhibitor of Casein Kinase 2 (CK2), Exhibits Anti-Tumor Activity in Hematologic Malignancies,

A Phase I/II Study of Vorinostat (SAHA), Cladribine (2-CdA), and Rituximab Shows Significant Activity in Previously Untreated Mantle Cell Lymphoma

Phase 1 Study of Tru-016, An Anti-CD37 SMIP™ Protein in Naïve and Relapsed and/or Refractory CLL Patients

Phase 1 Study of TRU-016, An Anti-CD37 SMIP™ Protein in Relapsed and/or Refractory NHL Patients

A Highly Selective AKT 1/2 Inhibitor Abrogates AKT Signaling and Is Cytotoxic to Primary Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma Cells

Clinical Safety and Activity In a Phase 1 Study of CAL-101, An Isoform-Selective Inhibitor of Phosphatidylinositol 3-Kinase P110δ, In Patients with Relapsed or Refractory Non-Hodgkin Lymphoma

Cladribine Plus Rituximab Is An Effective Therapy for Newly Diagnosed Mantle Cell Lymphoma

Forodesine, a Purine Nucleoside Phosphorylase (PNP) Inhibitor, Shows Clinical Activity In a Phase 2 Trial In Patients with Previously Treated Chronic Lymphocytic Leukemia (CLL) – Interim Analysis

Evaluation of CPX-351 (cytarabine:daunorubicin) Liposome Injection Anti-Leukemic Activity Against Primary Patient Leukemia Cells

P505-15, a Highly Selective SYK Inhibitor, Shows Significant Activity In Primary CLL Cells and Is Synergistic with Fludarabine at Low Concentrations

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only